BioWorld

April 3, 2003

View Archived Issues

Alvimopan Phase III Results Provide Adolor With Boost

Adolor Corp.'s stock hit a springboard, bouncing up about 31.3 percent Wednesday after the company released positive data from its first Phase III study of lead product alvimopan in the management of postoperative ileus.(BioWorld Today) Read More

Isis Cuts Staff, Curbs Programs Following Failure Of Affinitak

Read More

Alabamian Scientists Blow Cover On HIV/AIDS Virus' Quick-Change, Vaccine Defying, Escapist Artistry

Read More

Orchid Brings In $16M Through Private Sale Of Preferred Stock

Read More

MicroIslet Secures $12M For Preclinical Trials In Diabetes

Read More

Other News To Note

Read More